HCLTech and UiPath partner to accelerate agentic automation for global enterprises
HCLTech, a leading global technology company and UiPath (NYSE: PATH), a global leader in agentic automation, today announced a strategic partnership to accelerate agentic automation for UiPath customers globally. The partnership will drive large-scale transformation for enterprises across industries, enabling more intelligent and self-sufficient business process operations that require minimal human intervention.
HCLTech will leverage its AI expertise to deploy the UiPath Platform™, enabling autonomous operations in finance, supply chain, procurement, customer service, marketing and human resources. HCLTech will support this partnership with pre-configured AI agents and controls to ensure seamless deployment and scalability. The partnership aims to enhance business agility, optimize workforce efficiency and deliver faster returns on business process automation investments for global enterprises.
HCLTech will also establish an AI Lab with UiPath in India to develop Industry Focused Repeatable Solutions (IFRS) and MVPs for the full automation lifecycle, from strategy to implementation and continuous optimization. HCLTech will leverage its global delivery model to support UiPath customers in North America, Europe and Asia-Pacific.
"As we shift towards a new era with Agentic AI, agentic automation will be critical to provide businesses with the speed and agility to transform operations and unlock new business potential. Partnering with HCLTech allows UiPath to extend the power of its AI-powered automation to enterprises globally, accelerating intelligent transformation at scale. With HCLTech's deep expertise in AI, automation and industry solutions, UiPath customers will benefit from best-in-class implementation and business impact," said Ashim Gupta, Chief Operating Officer and Chief Financial Officer, UiPath.
"By co-creating next-gen AI-powered solutions with UiPath, HCLTech is setting new benchmarks for agentic autonomous operations that unlock unprecedented efficiency, agility and innovation for enterprises. Our proven expertise in hyper automation, AI and cloud-first architectures helps us provide industry-specific and advanced automation solutions at scale," said Raghu Kidambi, Corporate Vice President and Global Head, Digital Process Operations, HCLTech.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Standard
20 hours ago
- Business Standard
G.C Chemie Pharmie: Four Decades of Innovation and Trust in Pharmaceuticals and Nutraceuticals
India PR Distribution Mumbai (Maharashtra) [India], June 6: G.C Chemie Pharmie Pvt. Ltd. (GCCPL), a pioneer in India's pharmaceutical, nutraceutical, functional foods, and biopharmaceutical sectors, proudly celebrates over 44 years of innovation and service excellence. Founded in 1981 by visionary entrepreneur Gautam Shah, GCCPL has evolved into a globally connected and innovation-driven enterprise known for its commitment to trust, transparency, and quality. What began as an API trading and distribution firm has transformed into a diversified pharmaceutical powerhouse. GCCPL's impressive timeline of achievements includes: - 2009/2010: Acquisition of Eagle Chemical Works, establishing its own API manufacturing capabilities - 2009: Release of its first vaccine, marking a significant milestone in biopharmaceuticals - 2010/2011: Launch of its P2P division, introducing affordable medicines to the Indian market -2018: Entry into the sports nutrition space - 2022: Creation of a preventive healthcare division with a focus on gynecology and orthopedics - 2023: Establishment of a dedicated vaccine division to expand immunization solutions Driven by a mission to lead through innovative thinking and technology adoption, GCCPL delivers tailored solutions across pharmaceutical, nutraceutical, and functional food categories. The company continues to differentiate itself through its strong regulatory acumen, cutting-edge R & D, and a global network of manufacturing and distribution partners. "At GCCPL, innovation is not a buzzword--it's the foundation of our growth strategy," said Founder and Chairman Gautam Shah. "We're proud to be one of India's few private companies to bring the pneumococcal vaccine to the domestic market, second only to Pfizer." Recent product highlights include UC-II®, a patented undenatured type II collagen supplement, and Pylopass™, a breakthrough strain-based probiotic--both showcasing GCCPL's commitment to introducing clinically backed, innovative health solutions to India. With a sterling reputation for regulatory compliance, deep market research, and financial integrity--as affirmed by CRISIL's highest rating A2+ GCCPL stands as a trusted partner for businesses and healthcare providers seeking reliable, next-generation healthcare products. About G.C Chemie Pharmie Pvt. Ltd. Founded in 1981, GCCPL is an Indian-based pharmaceutical and nutraceutical company with a global footprint. Known for its reliability, innovation, and commitment to quality, GCCPL offers customized, technology-driven healthcare solutions to meet the evolving needs of today's market. The company maintains a strong presence in vaccines, preventive care, functional foods, and advanced supplements.
The Wire
a day ago
- The Wire
Noah Holdings and ARK Wealth Outline Strategic Wealth Allocation Framework for Navigating Market Volatility at Financial Forums in Hong Kong
HONG KONG, June 6, 2025 /PRNewswire/ — Noah Holdings Limited ('Noah' or the 'Company') (NYSE: NOAH and HKEX: 6686), a leading and pioneer wealth management service provider offering comprehensive one-stop advisory services on global investment and asset allocation primarily for global Chinese high-net-worth investors, and its internationally focused subsidiary, ARK Wealth Management, delivered key strategic … Continue reading "Noah Holdings and ARK Wealth Outline Strategic Wealth Allocation Framework for Navigating Market Volatility at Financial Forums in Hong Kong"
Time of India
a day ago
- Time of India
Leaderless and lagging: India's insurance overhaul stalls without Irdai head since March
Key reforms in India's insurance sector are stuck in limbo following the departure of Insurance Regulatory and Development Authority of India ( Irdai ) chairman Debashish Panda in March. With the top post still vacant since March, the sector is left without regulatory leadership at a time when several major initiatives are awaiting rollout, Times of India reported. The most ambitious of these is Bima Sugam , a centralised digital platform designed to allow customers to compare, purchase, and manage insurance policies online. Although each insurance company has already invested a few crore rupees into the development of this platform, the date of its official launch has still not been finalised. Alongside Bima Sugam, two other major initiatives—Bima Vistaar and Bima Vahaak—are also facing delays. Bima Vistaar is meant to offer bundled insurance coverage to rural populations, while Bima Vahaak is a distribution model driven by women. Both are facing technical and operational hurdles that have stalled their progress. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like An engineer reveals: 1 simple trick to get all TV channels Techno Mag Learn More Undo Plans to shift to a risk-based capital framework and align insurance accounting practices with the International Financial Reporting Standards (IFRS) are also in suspension. These changes were intended to modernise the sector's regulatory oversight and financial disclosures. However, industry unreadiness and lack of clarity around implementation have halted progress. Meanwhile, proposals to allow 100% foreign direct investment in the sector, permit composite licences, and introduce differentiated capital requirements have yet to be passed into law. Plans to list state-run insurers on the stock market are also stuck, facing pushback from within the public sector. Live Events Even as reforms stall, regulatory scrutiny has increased in some areas. The Reserve Bank of India and the finance ministry have raised concerns over banks and automobile dealers forcing customers to purchase bundled insurance products. Regulatory audits have uncovered several worrying practices in retail health insurance, including unclear reasons for claim rejections, steep premium increases, and poor portability. 'If the insurance industry is to grow the way mutual funds did after 2010, we need greater transparency, lower costs, and rebuilt trust,' said Kamesh Goyal, co-founder of Go Digit General Insurance . 'Sebi introduced direct plans and standard charges. Insurance could adopt similar guidelines—such as mandating refunds with interest when loss ratios fall below a certain level.' Goyal said that retail customers were effectively subsidising corporate clients. 'We're not saying distributors shouldn't earn, but loss ratios at 10% are unsustainable. A level of 60-65% is more realistic, accounting for costs and investment income. Once a fair value proposition is in place, mis-selling naturally comes down,' he said. Public sector insurers are also under pressure. Three have breached solvency norms. Even though insurance premiums have grown, the number of individual policyholders has stayed flat, which limits any real gains in financial inclusion. Surety bonds are another area that now demands regulatory attention. These bonds were introduced as substitutes for traditional bank guarantees. But insurers argue they come with higher risk as they lack the protections banks enjoy under existing bankruptcy laws. The delay in appointing a new Irdai chairman has slowed down reform at a time when the insurance industry is in urgent need of clear and forward-looking regulation. (with ToI inputs)
